HomeCompareVIEW vs PFE

VIEW vs PFE: Dividend Comparison 2026

VIEW yields 606.06% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIEW wins by $280371.12M in total portfolio value
10 years
VIEW
VIEW
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full VIEW calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — VIEW vs PFE

📍 VIEW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIEWPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIEW + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIEW pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIEW
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, VIEW beats the other by $179,917,761,305.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIEW + PFE for your $10,000?

VIEW: 50%PFE: 50%
100% PFE50/50100% VIEW
Portfolio after 10yr
$140185.61M
Annual income
$105,834,004,449.07/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VIEW
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-18.2
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIEW buys
0
PFE buys
0
No recent congressional trades found for VIEW or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIEWPFE
Forward yield606.06%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$280371.17M$51.1K
Annual income after 10y$211,667,981,687.60$27,210.54
Total dividends collected$274648.71M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: VIEW vs PFE ($10,000, DRIP)

YearVIEW PortfolioVIEW Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$71,306$60,606.06$9,161$701.38+$62.1KVIEW
2$480,183$403,885.93$8,610$859.79+$471.6KVIEW
3$3,055,680$2,541,883.57$8,366$1,081.25+$3.05MVIEW
4$18,386,820$15,117,242.14$8,483$1,405.66+$18.38MVIEW
5$104,687,331$85,013,433.96$9,084$1,907.24+$104.68MVIEW
6$564,382,839$452,367,394.46$10,418$2,732.78+$564.37MVIEW
7$2,883,114,581$2,279,224,943.60$13,007$4,193.56+$2883.10MVIEW
8$13,966,501,456$10,881,568,854.67$18,010$7,005.87+$13966.48MVIEW
9$64,208,586,900$49,264,430,341.75$28,216$12,979.89+$64208.56MVIEW
10$280,371,169,670$211,667,981,687.60$51,081$27,210.54+$280371.12MVIEW

VIEW vs PFE: Complete Analysis 2026

VIEWStock

View, Inc., a technology company, manufactures and sells smart building products. Its product portfolio includes View Smart Glass that comprise electrochromic glass panels in the form of insulating glass units; and View Net, a cloud-connected network infrastructure offering that can incorporate and power smart building devices. The company's products also include View Immersive Experiences, which transforms View Smart Glass windows into transparent, digital, and interactive surfaces; View Sense modules to measure and optimize light, humidity, temperature, air quality, dust, and noise; View Smart Protect, an intrusion detection solution that can be deployed on View Smart Glass windows to improve the security of a building by detecting glass breakage; View Secure Edge, a plug-and-play edge-to-cloud solution that enables IT and digital innovation teams to securely connect new and existing buildings to the cloud; View Remote Access, a secure access portal that enables IT teams to reduce the cost and cybersecurity risks of maintaining smart buildings; and View Building Performance, a configurable application and web-based tool that enables building managers to measure, optimize, and automate building performance; and View Workplace Experience, a configurable application and web-based tool that enables corporate facilities managers to create productive workplaces. It sells its products to real estate industry, including commercial offices, airports, hospitals and healthcare facilities, multi-family residential, and educational buildings. The company is headquartered in Milpitas, California.

Full VIEW Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VIEW vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIEW vs SCHDVIEW vs JEPIVIEW vs OVIEW vs KOVIEW vs MAINVIEW vs JNJVIEW vs MRKVIEW vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.